Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Canadian Surgery Forum 2018: St. John's, NL Sept. 13-15, 2018.

Canadian journal of surgery. Journal canadien de chirurgie·2022

Same author

COVID-19-Associated Carotid Atherothrombosis and Stroke.

AJNR. American journal of neuroradiology·2020

Same author

Response to letter of Dawson J. A, Brown A. W and Allison D. B: intervention for childhood obesity based on parents only or parents and child compared to follow-up alone.

Pediatric obesity·2018

Same author

Intervention for childhood obesity based on parents only or parents and child compared with follow-up alone.

Pediatric obesity·2018

Same author

A novel heterozygous IGF-1 receptor mutation associated with hypoglycemia.

Endocrine connections·2017

Same author

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.

Diabetes, obesity & metabolism·2016

Same journal

Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

International journal of clinical practice. Supplement·2015

Same journal

Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study.

International journal of clinical practice. Supplement·2015

Same journal

Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients.

International journal of clinical practice. Supplement·2015

Same journal

Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.

International journal of clinical practice. Supplement·2015

Same journal

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.

International journal of clinical practice. Supplement·2015

Same journal

Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF.

International journal of clinical practice. Supplement·2015

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Diabetes technology and the human factor.

A Liberman¹, B Buckingham, M Phillip

¹Schneider Children's Medical Center of Israel, Petah Tikva, Israel. mosheph@post.tau.ac.il

International Journal of Clinical Practice. Supplement

|February 18, 2011

Summary

This summary is machine-generated.

Understanding the human factor is crucial for developing effective diabetes technologies. Many patients with type 1 diabetes mellitus (T1DM) do not fully utilize available tools like insulin pumps and glucose sensors due to usability and psychological barriers.

More Related Videos

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Published on: March 15, 2024

Related Experiment Videos

Last Updated: Jun 4, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Generating Human Pancreatic Tissue Slices to Study Endocrine and Exocrine Pancreas Physiology

Published on: March 15, 2024

Area of Science:

Medical Technology
Human Factors Engineering
Psychology

Background:

Type 1 diabetes mellitus (T1DM) requires constant, 24/7 therapy adherence.
Despite advancements, many T1DM patients underutilize available technologies like insulin pumps and continuous glucose sensors.
The 'human factor' is critical for successful technology adoption in chronic disease management.

Purpose of the Study:

To review recent literature on human factors influencing the adoption and effective use of diabetes management technologies.
To identify reasons for underutilization of insulin pumps, glucose sensors, and self-monitoring of blood glucose (SMBG) devices.
To explore psychological factors affecting user acceptance and adherence to emerging glycemic control technologies.

Main Methods:

Literature review of papers published within the last year.
Focus on studies examining patient ability, willingness, and human factors in technology outcomes.
Inclusion of psychological literature to define user challenges (adherence, quality of life, motivation, executive functioning).

Main Results:

Patient's ability and willingness significantly impact the success of diabetes technologies.
Barriers to technology adoption include psychological and usability challenges, not just efficacy.
Specific patient groups may face greater difficulties in adopting new technologies.

Conclusions:

Future diabetes technology development must prioritize the 'human factor' from conception through post-production.
Addressing psychological barriers and improving user interface design are key to maximizing technology benefits for T1DM patients.
Further research is needed to enhance user acceptance and optimize the integration of emerging glycemic control technologies.